header image

News

Octapharma USA Sponsors NHF Annual Meeting, Shares Inspirational Bleeding Disorders Community Achievements

31.08.2017

Hoboken, New Jersey, August 29th 2017: Octapharma USA sponsored the National Hemophilia Foundation’s 69th Annual Meeting in Chicago and provided a patient symposium sharing the inspirational stories of three young men with...

Publication of clinical data demonstrating low immunogenicity and excellent efficacy of Nuwiq® in previously untreated patients

23.08.2017

Lachen, Switzerland, August 23rd 2017: Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously...

Octapharma symposium at ISTH Berlin supports progress in lifelong treatment of high-risk patients with Von Willebrand disease (VWD) and haemophilia A

11.07.2017

Lachen, Switzerland, July 11th 2017: Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As platinum sponsors...

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A

10.07.2017

Lachen, Switzerland, July 10th 2017: Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress,...

Octapharma activities prominent at the upcoming 2017 ISTH Congress in Berlin, Germany

06.07.2017

Lachen, Switzerland, July 6th, 2017 – Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress...

Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®

22.05.2017

Lachen, Switzerland, May 22nd 2017: Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to...

Octapharma Group publishes 2016 annual results reporting revenue of €1.6 billion and operating income of €383 million

01.03.2017

Lachen, Switzerland, March 1st, 2017: The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015. Octapharma achieved sales...